Loading clinical trials...

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

NCT04325217•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The primary objective is to confirm the incidence of adverse drug reactions (focus on gastrointestinal symptoms including diarrhoea and nausea) to Ofev Capsules seen in clinical trials with real world data generated in patients with SSc-ILD.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients in Japan with SSc-ILD who are prescribed with Ofev Capsules and have never been treated with Ofev Capsules before enrolment will be included.

Exclusion Criteria

•None.

Locations (1)

Nippon Boehringer Ingelheim Co., Ltd.

Tokyo, Japan

Key Dates

Start Date

May 27, 2020

Primary Completion Date

June 30, 2026

Completion Date

June 30, 2026

Last Updated

March 17, 2026

Enrollment

586

ACTUAL participants

Conditions

Lung Diseases, Interstitial

Interventions

Nintedanib

DRUG

Database for Interstitial Lung Disease

NCT04707781

Lung Diseases, Interstitial

View study

RECRUITINGNA

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

NCT06122233

Lung Diseases, InterstitialPulmonary Fibrosis

View study

RECRUITINGNA

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

Inclusion Criteria

Exclusion Criteria

Database for Interstitial Lung Disease

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases

Identification of Novel Markers of Human Lung Disease